Organon & Co. (NYSE:OGN) Reaches New 1-Year High – Should You Buy?

Organon & Co. (NYSE:OGN) shares hit a new 52-week high during trading on Wednesday . The company traded as high as $13.60 and last traded at $13.5850, with a volume of 473808 shares changing hands. The stock had previously closed at $13.54.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on OGN. BNP Paribas Exane restated a “neutral” rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research report on Wednesday, April 29th. Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 14th. Piper Sandler upgraded Organon & Co. from an “underweight” rating to a “neutral” rating and boosted their price target for the stock from $5.00 to $14.00 in a report on Tuesday, April 28th. Finally, Weiss Ratings upgraded shares of Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 15th. Five analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and an average price target of $11.40.

Organon & Co. Stock Up 0.3%

The company has a debt-to-equity ratio of 9.47, a current ratio of 1.97 and a quick ratio of 1.42. The company has a market capitalization of $3.56 billion, a P/E ratio of 14.59, a P/E/G ratio of 1.25 and a beta of 1.54. The stock has a 50-day moving average price of $13.18 and a 200-day moving average price of $9.50.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, April 30th. The company reported $0.71 EPS for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.49 billion. Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.Organon & Co.’s revenue was down 3.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.02 earnings per share. On average, research analysts predict that Organon & Co. will post 3.23 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 11th. Stockholders of record on Monday, May 11th were paid a $0.02 dividend. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, May 11th. Organon & Co.’s dividend payout ratio is currently 8.60%.

Insider Activity at Organon & Co.

In other news, SVP Lynette Holzbaur acquired 26,448 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The stock was bought at an average cost of $13.35 per share, for a total transaction of $353,080.80. Following the completion of the transaction, the senior vice president directly owned 52,851 shares in the company, valued at $705,560.85. This represents a 100.17% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.62% of the company’s stock.

Hedge Funds Weigh In On Organon & Co.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Organon & Co. by 2.7% during the 4th quarter. Vanguard Group Inc. now owns 36,916,382 shares of the company’s stock worth $264,690,000 after acquiring an additional 987,979 shares during the period. State Street Corp lifted its stake in shares of Organon & Co. by 2.8% in the 4th quarter. State Street Corp now owns 9,597,761 shares of the company’s stock valued at $68,816,000 after purchasing an additional 262,185 shares during the period. AQR Capital Management LLC lifted its stake in shares of Organon & Co. by 105.2% in the 4th quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock valued at $61,282,000 after purchasing an additional 4,394,814 shares during the period. Private Management Group Inc. boosted its position in shares of Organon & Co. by 38.3% during the 4th quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock valued at $31,169,000 after purchasing an additional 1,204,979 shares in the last quarter. Finally, UBS Group AG boosted its position in shares of Organon & Co. by 55.2% during the 4th quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock valued at $30,795,000 after purchasing an additional 1,527,492 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.